CMTx Biotech Revenue and Competitors
Estimated Revenue & Valuation
- CMTx Biotech's estimated annual revenue is currently $1.6M per year.
- CMTx Biotech's estimated revenue per employee is $155,000
Employee Data
- CMTx Biotech has 10 Employees.
- CMTx Biotech grew their employee count by -9% last year.
CMTx Biotech's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder and CEO | Reveal Email/Phone |
CMTx Biotech Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is CMTx Biotech?
CMTx Biotech is a clinical-stage biopharmaceutical company that is aggressively developing an orally-administered small molecule for the treatment of COVID-19 patients. The company is currently preparing to advance into a Phase II clinical trial to demonstrate the safety and efficacy of our lead drug candidate in hospitalized COVID-19 patients. Our clinical-stage drug candidate has already demonstrated impressive efficacy in a number of animal models of acute respiratory distress syndrome (ARDS) across multiple species (rats, mice, pigs, sheep). It has also been evaluated in several Phase I/II clinical studies, which showed that the drug is well-tolerated. CMTx Biotech also has a pipeline of pre-clinical stage analogues for the treatment of rare diseases.
keywords:N/AN/A
Total Funding
10
Number of Employees
$1.6M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.9M | 10 | 11% | N/A |
#2 | $1M | 12 | 140% | N/A |
#3 | $4M | 26 | 8% | N/A |
#4 | $3.9M | 34 | 36% | N/A |
#5 | $9.1M | 35 | 84% | N/A |